AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announces AIRSUPRA® (albuterol/budesonide), is now commercially available in the US by prescription. AIRSUPRA received FDA approval in January 2023 for the as-needed treatment or prevention of symptoms of asthma and to help prevent sudden severe breathing problems (asthma attacks) in people aged 18 years and older.1 AIRSUPRA contains a short-acting beta2-agonist (SABA), to help relax the smooth muscles of the airways, and an inhaled corticosteroid (ICS), to he ...